MX2023001411A - Formulaciones para particulas virales altamente purificadas. - Google Patents
Formulaciones para particulas virales altamente purificadas.Info
- Publication number
- MX2023001411A MX2023001411A MX2023001411A MX2023001411A MX2023001411A MX 2023001411 A MX2023001411 A MX 2023001411A MX 2023001411 A MX2023001411 A MX 2023001411A MX 2023001411 A MX2023001411 A MX 2023001411A MX 2023001411 A MX2023001411 A MX 2023001411A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- particles
- highly purified
- viral particles
- purified viral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Manufacturing & Machinery (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063128P | 2020-08-07 | 2020-08-07 | |
| US202063063108P | 2020-08-07 | 2020-08-07 | |
| PCT/US2021/044955 WO2022032104A1 (en) | 2020-08-07 | 2021-08-06 | Formulations for highly purified viral particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001411A true MX2023001411A (es) | 2023-05-15 |
Family
ID=80114720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001411A MX2023001411A (es) | 2020-08-07 | 2021-08-06 | Formulaciones para particulas virales altamente purificadas. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220040305A1 (enExample) |
| EP (1) | EP4192437A4 (enExample) |
| JP (1) | JP2023536883A (enExample) |
| KR (1) | KR20230049670A (enExample) |
| CN (1) | CN116323925A (enExample) |
| AU (1) | AU2021320395A1 (enExample) |
| CA (1) | CA3190596A1 (enExample) |
| IL (1) | IL300323A (enExample) |
| MX (1) | MX2023001411A (enExample) |
| WO (1) | WO2022032104A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116096867A (zh) * | 2020-06-02 | 2023-05-09 | 詹森生物科技公司 | 用于病毒纯化的材料和方法 |
| US20230090654A1 (en) * | 2021-08-24 | 2023-03-23 | Homology Medicines, Inc. | Adeno-associated virus formulations |
| EP4651883A1 (en) * | 2023-01-19 | 2025-11-26 | uniQure biopharma B.V. | Pharmaceutical formulations of gene delivery vehicles |
| KR20260019635A (ko) * | 2023-06-09 | 2026-02-10 | 사르토리우스 비아이에이 세퍼레이션스 디.오.오. | 완전 충전 아데노 관련 바이러스 (aav) 캡시드의 향상된 분리 방법 |
| WO2025045083A1 (zh) * | 2023-09-01 | 2025-03-06 | 康霖生物科技(杭州)有限公司 | 一种液体制剂及其用途 |
| WO2025114524A1 (en) * | 2023-11-30 | 2025-06-05 | Uniqure Biopharma B.V. | Formulations for viral drug products |
| CN118957152B (zh) * | 2024-08-30 | 2025-11-25 | 浙江恒驭生物科技有限公司 | 一种腺相关病毒载体基因组滴度检测方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5118798B2 (ja) * | 2000-03-07 | 2013-01-16 | メルク・シャープ・エンド・ドーム・コーポレイション | アデノウイルス製剤 |
| BRPI0511764B8 (pt) * | 2004-06-01 | 2021-05-25 | Avigen Inc | método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav |
| GB201513010D0 (en) * | 2015-07-23 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel formulation |
| IL258005B2 (en) * | 2015-09-17 | 2025-01-01 | Res Inst Nationwide Childrens Hospital | Methods and materials for gene therapy for beta-4,1-N-acetylgalactosaminyltransferase 2 |
| US12070702B2 (en) * | 2018-06-14 | 2024-08-27 | Regenxbio Inc. | Anion exchange chromatography for recombinant AAV production |
| CN112770812A (zh) * | 2018-07-24 | 2021-05-07 | 沃雅戈治疗公司 | 产生基因治疗制剂的系统和方法 |
| TW202332458A (zh) * | 2019-04-19 | 2023-08-16 | 美商銳進科斯生物股份有限公司 | 腺相關病毒載體調配物及方法 |
-
2021
- 2021-08-06 CA CA3190596A patent/CA3190596A1/en active Pending
- 2021-08-06 IL IL300323A patent/IL300323A/en unknown
- 2021-08-06 US US17/396,090 patent/US20220040305A1/en not_active Abandoned
- 2021-08-06 WO PCT/US2021/044955 patent/WO2022032104A1/en not_active Ceased
- 2021-08-06 AU AU2021320395A patent/AU2021320395A1/en not_active Abandoned
- 2021-08-06 EP EP21853878.3A patent/EP4192437A4/en active Pending
- 2021-08-06 CN CN202180067655.9A patent/CN116323925A/zh active Pending
- 2021-08-06 MX MX2023001411A patent/MX2023001411A/es unknown
- 2021-08-06 KR KR1020237007796A patent/KR20230049670A/ko not_active Withdrawn
- 2021-08-06 JP JP2023507428A patent/JP2023536883A/ja active Pending
-
2025
- 2025-11-04 US US19/379,616 patent/US20260061059A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3190596A1 (en) | 2022-02-10 |
| US20220040305A1 (en) | 2022-02-10 |
| KR20230049670A (ko) | 2023-04-13 |
| EP4192437A1 (en) | 2023-06-14 |
| WO2022032104A1 (en) | 2022-02-10 |
| IL300323A (en) | 2023-04-01 |
| EP4192437A4 (en) | 2024-09-25 |
| AU2021320395A1 (en) | 2023-04-13 |
| JP2023536883A (ja) | 2023-08-30 |
| US20260061059A1 (en) | 2026-03-05 |
| CN116323925A (zh) | 2023-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001411A (es) | Formulaciones para particulas virales altamente purificadas. | |
| WO2020016659A3 (en) | Multiparticulate formulations of cannabinoids | |
| WO2021217004A3 (en) | Methods and compositions for treating virus-associated inflammation | |
| JP5892149B2 (ja) | ソフトコンタクトレンズ用組成物及び吸着抑制方法 | |
| PE20241346A1 (es) | Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones que los comprenden | |
| MY197773A (en) | Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody | |
| JP5519001B2 (ja) | コルチコステロイドおよびシクロデキストリンを含む局所用溶液処方物 | |
| MX2021012564A (es) | Formulaciones y métodos de vectores de virus adenoasociados. | |
| SA523440384B1 (ar) | مركبات الفوسفوليبيدات واستخداماتها | |
| MX2023006471A (es) | Composiciones farmaceuticas mejoradas que contienen vector viral adenoasociado. | |
| TW200716157A (en) | Pharmaceutical formulations and methods of treatment using the same | |
| ZA201803678B (en) | Pharmaceutical composition | |
| MX2022012359A (es) | Formulacion. | |
| MY197527A (en) | Preventive and curative peroxometallate based composition, notably pharmaceutical composition | |
| ZA201908610B (en) | Il-15 protein complex pharmaceutical composition and uses thereof | |
| MX2022008949A (es) | Formulacion de anticuerpos estable. | |
| WO2021070200A3 (en) | Stable compositions of (7as,2's)-2-oxoclopidogrel and its pharmaceutical salts | |
| MY209656A (en) | Compositions and methods of enhancing 5-hydroxytryptophan bioavailability | |
| DK1906916T3 (da) | Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser | |
| PH12021551811A1 (en) | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same | |
| MX2019014666A (es) | Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo. | |
| MX2025010834A (es) | Formulaciones de un profarmaco antiviral | |
| AR125366A1 (es) | Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico | |
| PE20171061A1 (es) | Composiciones farmaceuticas de accion prolongada para hepatitis c | |
| AR131641A1 (es) | Formulación de lanifibranor |